Acuamark Diagnostics, Inc.

07/03/2024

Happy 4th of July!

Acuamark is wishing everyone a safe and joyous Independence Day filled with celebration and pride. As we celebrate our nation’s freedom, it is important we reflect on the need for equity and healthcare accessibility for all.

According to a recent NPR report, 50% of U.S. military bases are situated in federally designated healthcare deserts. At Acuamark, we recognize the importance of developing early detection technologies that are cost effective and easily accessible, bridging these gaps and ensuring that our service members receive the care they deserve.

Together, let's innovate for health equity.

05/31/2024

Join Acuamark's CEO at .

On Thursday, June 6, Bernard Peperstraete will speak on the panel “Competing as a Diagnostic Company in the Current Funding Environment: New Funding Models.”

We’re looking forward to an engaging discussion on the diagnostics industry's current funding landscape and new strategies for the future.

04/09/2024

President Joe Biden has declared April 2024 as Cancer Prevention and Early Detection Month, urging citizens, government agencies, businesses, nonprofits, and other groups to raise awareness about cancer prevention, detection, and treatment. (bit.ly/3xuLKZH)

Despite significant progress, the fight against cancer continues. At Acuamark, we're developing novel technology for early cancer detection with our innovative technology. By detecting cancer-specific DNA methylation using PCR technology, we aim to revolutionize early detection, making it as accessible as in-clinic COVID tests.

Learn more about our work and stay updated: acuamarkdx.com

Cancer has touched nearly every American family. During National Cancer Prevention and Early Detection Month, we honor the enormous courage and strength of the millions of Americans facing the disease today and of the many millions of survivors, whose resilience inspires us all. Together, we will en...

03/13/2024

It’s Colorectal Cancer (CRC) Awareness Month, and Acuamark is pleased to be among the innovators bringing forward new technologies to make screening and monitoring for CRC more reliable, cost-effective and accessible to all.

Acuamark’s blood-based assays target the detection of methylation patterns indicative of cancer. Methylations are among the earliest indicators of cancer. Utilizing entirely novel, straightforward and easily integrated qPCR-based methods, our technology is designed to achieve highly accurate detection results and provide a richly nuanced readout – even in the initial stages of cancer.

That’s important because CRC is one of the most widespread – but preventable – cancers, and more than 100 million Americans are eligible to be screened. Follow our progress on our website!

acuamarkdx.com

02/29/2024

Join the American College of Gastroenterology (ACG) in recognizing "Dress in Blue Day" tomorrow, March 1, 2024, rallying the GI community to wear blue and show support for lifesaving colorectal cancer screening.

Early detection is key in the fight against colorectal cancer. At , we're dedicated to developing novel technologies for early cancer detection, aiming to unlock massive benefits for patients and society at large.

Discover resources developed by ACG experts on the College's website! Link in comments.

02/26/2024

Get ready with us for Colorectal Cancer Awareness Month in March!​

Colorectal Cancer Awareness Month was established in the year 2000 with the goal to raise awareness, focus on research, support those affected by colorectal cancer and encourage health-promoting behaviors – like getting screened.​

​At , we understand that recurrent, accurate testing and monitoring can enable cancer detection at early stages, when treatment is most effective and affordable. That's why we're developing novel technology to make it happen. Learn more about our progress and follow our news on our website.​

acuamarkdx.com​

02/01/2024

At AcuamarkDx, we're working to "Close the Care Gap" to support this year's World Cancer Day theme.

Recent data from the Kaiser Family Foundation show that Black Americans continue to face the highest cancer mortality rate, partly due to diagnosis at later stages of disease, when it's harder to treat.

We're developing novel technology that detects cancer-specific methylation with a simple PCR test as part of routine primary care checkups. Our mission is to ensure everyone has access to accurate, cost-effective cancer diagnosis at the earliest stages, shifting the paradigm for patients.

Learn more about World Cancer Day and follow our progress at our website. Links below in the comments.

01/18/2024

This week, the American Cancer Society released its Cancer Facts and Figures for 2024, projecting more than 2 million new cancer cases this year for the first time ever.

At AcuamarkDx, we’re responding to this important challenge by advancing our novel technology for early cancer detection and frequent recurrence monitoring. Our innovative approach detects cancer-specific DNA methylation with PCR technology, making early-cancer detection as easy as an in-clinic COVID test.

We’re more motivated than ever by the latest findings and the increasing need for early detection methods that are first and foremost reliable, but also cost-effective, accessible and efficient for patients and physicians.

01/15/2024

Today, we honor Dr. Martin Luther King Jr.'s work and legacy of justice, equality and acts of service. Inclusion is at the core of our mission, recognizing diversity as the driving force behind our innovation and success in the global fight against cancer. Together, we reflect on the dreams and values of Martin Luther King.

01/03/2024

Meet Ezeddin Fadel, MD, our Clinical Research Manager of Biorepository.

Ezeddin shares his motivation for joining the AcuamarkDx team: "I worked in therapeutic oncology trials for more than 7 years. Although it is important to research viable cancer treatments, I am deeply committed to making a meaningful impact in the fight against cancer. The diagnostics field offers a unique opportunity to be at the forefront of cutting-edge medical technology for early cancer detection. And working at Acuamark is enabling me to be part of a team dedicated to pushing the boundaries of science and medicine to address this challenge."

12/31/2023

Recent findings from UT Southwestern Medical Center highlight a crucial challenge in colorectal cancer screening: about 10% of at-home tests are unusable, mostly due to patient errors. This underscores the need for more reliable and cost-effective early detection methods.

At Acuamark, we're dedicated to developing simple, convenient and accurate blood-based cancer detection technologies. Early detection saves lives; our goal is to make it a standard part of primary care. Learn more about our mission and innovative approach at our website. Link in comments.

Despite the convenience of at-home screening tests for early detection of colorectal cancer (CRC), a study led by UT Southwestern Medical Center researchers examining more than a decade of patient data found that about 10% of the tests could not be processed, mostly due to patient error.